Loading...
•
Dec 31, 2019
Black Diamond Therapeutics Q4 2019 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported its Q4 and full year 2019 financial results. The FDA allowed the IND application for BDTX-189, and the company initiated a Phase 1/2 clinical trial. Black Diamond believes that the $316 million raised since November, including via its IPO, will enable them to execute the clinical development of BDTX-189, continue to invest in their MAP platform, and progress their early stage pipeline.
FDA allowed the IND application for BDTX-189 in December and initiated Phase 1/2 clinical trial
Company started enrolling and dosing patients in Phase 1/2 clinical trial
Cash and cash equivalents of $154.7 million as of December 31, 2019
Completed IPO in February 2020 raised approximately $231.3 million in gross proceeds
Forward Guidance
The company did not provide specific financial guidance for future periods.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...